Survival protein may prevent collateral damage during cancer therapy ...Middle East

- News
Survival protein may prevent collateral damage during cancer therapy
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, and the discovery has shed light on how this damage occurs at the molecular level.

Hence then, the article about survival protein may prevent collateral damage during cancer therapy was published today ( ) and is available on ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Survival protein may prevent collateral damage during cancer therapy )

Apple Storegoogle play

Last updated :

Also on site :